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Summary: The concentration of haptoglobin in sera of healthy women and patients with non-malignant and malig-
nant ovarian tumours was measured by two methods, i.e. complex formation with haemoglobin and complex
formation with concanavalin A. High correlation (r = 0.74) between both the methods was found in the group of
healthy women, but correlation coefficients were much lower in the group of non-malignant and malignant tumours
(r = 0.42 and 0.37, respectively). Direct determinations of haptoglobin, and calculation of the ratio of haptoglobin
bound to concanavalin A to haptoglobin bound to haemoglobin revealed statistically significant differences among
the examined groups. Comparison of two methods of haptoglobin quantitation suggest that processes connected
with ovarian disorders may alter the glycosylation of haptoglobin oligosaccharide chains.
Introduction
Haptoglobin is a genetically determined a2-^acid glyco-
protein, present in most body fluids. The oligosaccharide
moiety of haptoglobin consists of N-acetylglucosamine,
mannose, galactose, fucose, and sialic acid, forming bi-
and trianntennary N-linked glycans. Haptoglobin is an
"acute phase" reactant. Its plasma level is increased in
malignancy, trauma, infection, inflammation, tissue
damage, but decreased in haemolytic conditions, and
since haptoglobin is synthesised in the liver (1) it is also
decreased in severe hepatocellular deficiency.
Haptoglobin (Hp) is known to form with haemoglobin
(Hb) a stable, practically irreversible complex (Hp-Hb),
which in vitro has the activity of a "true" peroxidase.
This property is exploited for the quantitative determina-
tion of haptoglobin (2). Formation of the Hp-Hb com-
plex is a function of the polypeptide moiety of haptoglo-
*) This work was supported by the State Committee for Scientific
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bin (1). On the other hand, the specific arrangement of
carbohydrates in haptoglobin enables it to bind plant lee-
tins. The reactivity of the mannose-type core of hapto-
globin with concanavalin A, which was utilized in the
lectin-ELISA estimation of haptoglobin in body fluids,
may change with alterations in haptoglobin glycosyla-
tion (3). Thus, changes in the measured concentrations
of haptoglobin under various pathological conditions
could be related to quantitative differences in hepatic
haptoglobin synthesis, or/and to qualitative differences
in the haptoglobin glycans.
Complex metabolic processes occuring in cancer include
changes in structure and composition of the oligosaccha-
ride chains of glycoproteins (increases/decreases in the
content of specific carbohydrates, changes in antennary
structure). These phenomena are very relevant clini-
cally (4, 5).
In our previous paper haptoglobin determinations (by
means of haemoglobin binding) in sera of patients with
ovarian cancer were used to monitor the effects of che-
motherapy (6). We also demonstrated some differences
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in the quantitation of haptoglo in in pathological body
fluids, between the "traditional" Hp-Hb method and the
method based on Hp-concanavalin A complex formation
(7). The purpose of the present study was to investigate
whether these reactivities of haptoglobin, as determined
in the sera of patients with ovarian tumours, might be
used as an index of disease activity.
Materials and Methods
Samples
Control group (Group I) was established with sera from 37 healthy
non-pregnant women (28-57 years old), attending medical follow-
up in the Medical Diagnostic Centre in Wroclaw. Serum samples
were chosen for their normal haptoglobin values and on the basis
of routine laboratory tests (erythrocyte sedimentation rate, activi-
ties of aminotransferases and acid phosphatase, glucose concentra-
tion etc.). Non-haemolysed serum samples were stored at -20 °C
until analysed.
Pathological sera were collected from 99 women attending the
Clinic of Gynaecology of Wroclaw University of Medicine. These
preoperative patients were divided into two groups. Group II sam-
ples were taken from 56 women (25-61 years old) with non-ma-
lignant gynaecologic tumours (cysts, myomas). Sera from 43 pa-
tients (31—77 years old), suffering from ovarian carcinomas (FIGO
stages II-IV) were assigned to Group III. The staging was per-
formed according to FIGO rules (8).
The procedure of the assay was as follows: wells of the polystyrene
microtitre plate were incubated at 37 °C for 3 h with 0.1 g/1 con-
canavalin A in acetate buffer 0.1 mol/1, pH 6.0, containing
1 mmol/1 of each cation: Ca2+, Mg2+ and Mn2+. The plate was
then washed 4 times with washing buffer (0.005 mol/1 HEPES, pH
7.2, containing 0.15 niol/1 NaCl, 0.5 ml/1 Tween 20, 0.2 g/1 thiom-
ersal and 1 mmol/1 of divalent ions Ca2+, Mg2+, Mn2+). After
blocking with 5 g/1 bovine serum albuniih, 100 μΐ of haptoglobin
standard solutions (10-100 ng/well) and 100 μΐ of diluted test
samples (usual dilutions: 5000 and 10000 times) were added and
incubated for l h at 37 °C. After washing 4 times with washing
buffer containing 20 g/1 polyethylene glycol 6000 (PEG), 100 μΐ of
anti-Hp monoclonal antibody (clone 7.60.66.55) conjugated with
peroxidase diluted (2000 times) with washing buffer (see above)
was dispensed and the plate was incubated for 30 min at 37 °C.
The plate was washed and the enzymatic activity was developed
with 0-phenylenediamine. The absorbance was read at 492 nm
against a reference wavelength on a Hamilton UV HR 7000
ELISA reader.
Samples were analysed in triplicate after two dilutions to avoid an
excess of glycoprotein. Controls were included for each experl·
ment. Background absorbances (with buffer instead serum, but with
all other reagents) ranged from 0.3 to 0.5, depending on the plate
and day of the experiment. Absorbance values for negative control
(human serum without haptoglobin confirmed by Hp-Hb-ELISA
(7)) were the same as background.
The amount of haptoglobin bound to concanavalin A was calcu-
lated from a standard curve prepared for each plate. The useful
range of the standard curve was 50—600 μg/l. A standard prepara-
tion of haptoglobin containing 0.2% fucose, 2.6% mannose, 2.0%
N-acetylglucosamine, was used (9).
Quantification of haptoglobin based on its reactivity
with haemoglobin
The Hp-Hb complex displays "true" peroxidase activity. The cleav-
age of hydrogen peroxide is indicated by guaiacol according to
Jones & Mould (2), as follows. Wells of the microtitration plate
were cleaned and washed and used in place of small tubes. To the
wells were added:
- 50 μΐ of Hp standard (5-300 mg/1 9 g/1 NaCl) or 5 μΐ of serum
sample in 50 μΐ of 9 g/1 NaCl
- 50 μΐ 0.5 g/1 horse methaemoglobin solution.
The control reagent sample containing all reagents and 50 μΐ of
saline instead of Hp was included in each series of estimations. A
"blank" was prepared for each serum, containing the reagents and
serum sample but without methaemoglobin. The plate was incu-
bated for 10 min in room temperature, followed by addition of 150
μΐ of guaiacol reagent (6.82 g guaiacol, 183 ml of 1 mol/1 acetic
acid added to 700 ml distilled water, adjusted to pH 4.0, then made
up to 1 litre with distilled water) and 50 μΐ of 0.02 mol/1 hydrogen
peroxide solution. After 5 min, absorbance at 492 nm was mea-
sured in a Hamilton HR 7 000 reader. Serum haptoglobin concen-
tration was caluclated from a standard curve prepared for each
plate.
Quantification of haptoglobin based on its reactivity
with concanavalin A
The conditions of the assay for glycosylated haptoglobin bound to
concanavalin A have been described in 1. c. (3). The lower detec-
tion limit of the assay calculated as 3 SD for the mean of the blank
sample was 50 μg/l. The intra-assay (within-day) and inter-assay
(between day) coefficients of variation were 4-7% and 6-9%,
respectively, as analysed using sera with low, medium and high
contents of haptoglobin bound to concanavalin A. The recovery
of haptoglobin bound to concanavalin A in the presence of other
glycoproteins was higher than 97%.
Statistical calculations
The average, median and standard deviation, lower and upper quar-
tile, distribution of variables, correlation coefficient r and prob-
ability level among the examined groups (Wilcoxon test) were cal-
culated.
Results
Haptoglobin concentration was estimated in sera of pa-
tients with non-malignant (Group II) and malignant
(Group III) ovarian tumours as compared with control
healthy women (Group I). The determinations were car-
ried out in parallel, using two methods i. e. complex for-
mation with Hb and complex formation with concana-
valin A (fig. 1). Correlation coefficients for both meth-
ods were: in the control group r = 0.74, in the group
of non-malignant tumours r = 0.42, and in the cancer
group r = 0.37.
Table 1 summarises the statistical data of the Hp-con-
canavalin A and Hp-Hb determinations. The ratio of Hp-
concanavalin A to Hp-Hb was also calculated. In the
control group, the three measured values are rather sim-
ilar (approximately 1). In the group of non-malignant
tumours the mean value for Hp-Hb was twice as high as
in the control group, while Hp-concanavalin A was only
a little higher. In the group of ovarian cancers Hp-Hb
was more than three times and Hprconcanavalin A more
than four times higher than in the'control group. In both
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Fig. 1 Comparison of haptoglobin concentrations measured by
the reaction with haemoglobin (empty bars) and with concanavalin
A (black squares) in healthy women (a), patients with non-malig-
nant tumours (b) and with ovarian cancers (c).
pathological groups the mean values of the ratio were
0.83 and 1.24, with similar high SD values caused by
extreme variation of individual results (fig. 1).
The results were analysed by means of the Pearson (χ2)
and Wilc xon tests at ρ = 0.05. The values for Hp in the
control group showed a normal distribution, whereas the
distribution was not normal in the other two groups. The
following statistically significant differences were
found in:
Hp-Hb level - Group 1 vs. Group II and Group ΙΠ;
Group Π vs. Group ill.
Hp-ConA - Group I vs. Group III;
level Group Π vs. Group III.
Ratio - Group I vs. Groups III;
Group II vs. Group ΙΠ.
Individual data (fig. 1) as well as statistical analysis (tab.
1) show relatively wide distribution of results in both
pathological groups. In order to visualize "normal",
higher and lower values of Hp-Hb, Hp-concanavalin A
and ratio in these groups, we established certain limits
(means ± 2 SD) based on the measurements in the con-
trol group. There were: Hp-Hb = 0.44-1.56 g/1, Hp-
concanavalin A = 0.35-1.51 g/1, ratio = 0.45-1.49.
As can be seen in figure 2, the majority of Hp-Hb and
Hp-concanavalin A determinations in the pathological
groups remained outside the limits (more than 70% and
about 60%, respectively). Differences in Hp-Hb and Hp-
concanavalin A measurements are also apparent in the
ratio. Thus, in the group with non-malignant tumours
10% of the ratio values were higher, 30% lower and
60% normal, whereas in the cancer group 30% of the
respective results were higher, 40% lower and only
30% "normal".
It is worth pointing out that the ratio in pathological
groups was "normal" in some cases when the Hp-Hb
was abnormal or was "off-limits" when Hp-Hb was
"normal". For instance Hp-Hb and Hp-concanavalin A
concentrations in a patient with ovarian cancer were ex-
tremely high: 6.7 g/1 and 7.3 g/1, respectively, hence the
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ratio (= 0.92) was "normal". Another case in which
both Hp values were abnormally low (approximately 0.3
g/1) the ratio (= 1.0) was "normal". Perhaps more inter-
esting are those cases where both determinations are in-
compatible. For instance, Hp-Hb values of 1.65, 1.02
and 1.39 g/1, Hp-concanavalin A values of 3.5, 0.3 and
4.25 g/1, resulting in ratios of 2.12, 0.29 and 3.06,
respectively.
Discussion
Of all gynaecologic malignancies ovarian cancer has the
lowest overall survival rate. Most patients have ad-
vanced stage disease at the time of diagnosis. Monitor-
ing and detection of subclinical disease is limited be-
cause the majority of patients have no measurable dis-
ease. Many biochemical and immunological quantities
have been used, but none has fulfilled the criteria of an
ideal tumour marker (10—13). Although failing to meet
such criteria, haptoglobin measurements have been use-
ful in assessing the disease status of ovarian cancer pa-
tients, particularly during chemotherapy, and have
helped to decide on surgery or a "second-look" opera-
tion (6, 14).
Tab. 1 Haptoglobin (Hp) levels estimated from haemoglobin
(Hb) and concanavalin A (ConA) reactivities in sera of patients
with ovarian tumours.
Groups Hp-Hb
g/I
I. Normal sera
n = 37
Mean value ± SD l .0 ± 0.28
Median 1.07
Range of values 0.5 -1.50
Lower quartile 0.8
Upper quartile 1.17
II. Non-malignant tumours
n = 56
Mean value ± SD 2. 10 ± 1 .62
Median 1.69
Range of values 0 - 8.06
Lower quartile 0.99
Upper quartile 2.74
HI. Ovarian cancers
n = 43
Mean value ± SD 3.43 ± 2.30
Median 2.86
Range of values 0.24 - 8.26
Lower quartile 1.5
Upper quartile 5.11
Hp-Hb - haptoglobin level
haemoglobin (2).
Hp-ConA - haptoglobin level
Hp-ConA
g/1
0.93 ± 0.64
0.96
0.38- 1.7
0.7
1.1
1.19± 1.01
0.9
0 - 3.85
0.3
1.7
3.82 ± 4.25
1.44
0.06 - 16
0.98
6.6
measured by the
measured by the
Ratio
Hp-ConA/
Hp-Hb
0.97 ± 0.26
0.91
0.55 - 1.4
0.74
1.2
0.83 ± 0.96
0.54
0.03 - 4.9
0.38
0.8
1.24 ± 1.19
0.71
0.02 - 4
0.36
2.1
reaction with
reaction with
concanavalin A (3).
SD - standard deviation
It is well documented that quantitative changes in the
concentrations of acute phase proteins during certain
pathophysiological states, particularly in inflammatory
conditions and cancer, often accompany specific alter-
ations of the carbohydrate moieties of glycoproteins.
Changes in the degree of branching (major micro-
heterogeneity) or/and in terminal glycosylation of glyco-
proteins (minor microheterogeneity) originate from
modifications in the post-translational glycosylation
mechanism in the liver or from degradative processes in
the circulation (4, 5, 15, 16).
The introduction of affinity chromatography and crossed
affinity electrophoresis of haptoglobin with plant lectins
(concanavalin A and wheat germ agglutinin), leading to
the appearance of several microheterogeneous forms,
was shown to be of value in the differential diagnosis of
ovarian cancer and other inflammatory conditions. The
carbohydrate moiety of haptoglobin from ascitic fluids
of patients with ovarian carcinoma was apparently
changed as judged from the reactions with haemoglobin
and concanavalin A (17, 18). Investigations of ovarian
cancer haptoglobins using digoxigenin-labelled lectins
suggest that normal and ovarian cancer haptoglobins dif-
fer in their content of carbohydrate structures containing
sialic acid-linked a(2—6) or a(2—3) to galactose and in
the type of glycan branching (9). Turner's group (19-
22) has shown that ovarian cancer sera have high levels
of an abnormal form of haptoglobin in which fucose
occupies three positions (mainly a(l—3)) in carbohy-
drate chains. The fucose content of haptoglobin was ele-
vated 7-fold in ovarian cancer. The increased fucosyla-
tion of haptoglobin was closely related to tumour burden
and also correlated with the serum levels of α-3-fiicosyl
transferase. Analyses of galactose and N-acetylglucos-
amine contents of haptoglobin suggest that there are
more oligosaccharide branches on the "cancer haptoglo-
bin".
Hp-Hb Hp-Con A Ratio
30%
36%
._ 23%
75%
60%
30%
42%
40%
30%
Fig. 2 Distribution of haptoglobin concentrations in patient sera
with non-malignant tumours (a) and ovarian cancers (b).
Results are expressed as a percentage of D "normal", B higher, and
D lower Hp measurements at established limits (means ± 2 SD).
The distribution of values in the pathological groups was related
to the limits established for the control group: Hp-Hb = 0.44-1.56
g/1; Hp-concanavalin A = 0.35-1.51 g/1,»ratio = 0.45-1.49.
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The present work shows the amount of haptoglobin that
can react with concanavalin A in sera from women with
ovarian tumours. We compared these levels with hapto-
globin concentrations as measured by the traditional
haptoglobin-haemoglobin peroxidase method (2). Com-
parisons were expressed as ratio values of Hp-concana-
valin A to Hp-Hb. The lectin concanavalin A binds with
bi-, but not tri- or tetraantennary N-linked glycans, but
the presence of an additional bisecting GlcNAc residue
on the Man of the biantennary units inhibits this binding.
The degree of reactivity with concanavalin A depends
on the number of biantennary structures present on the
molecule and could help to reveal major microhetero-
geneity in glycoproteins.
Measurements of Hp-concanavalin A and Hp-Hb in the
present paper provide interesting data on the differential
diagnosis of malignant against non-malignant ovarian
tumours, as well as non-malignant tumours against other
physiological states (see statistically significant differ-
ences). In both pathological groups, about 60% of results
were "off limits" (fig. 2). Moreover some differences in
Hp-concanavalin A concentrations between non-malig-
nant and malignant groups were observed, namely, 31%
and 33% of results in non-malignant vs. 9 and 49% in
malignant sera were lower and higher than "normal",
respectively. In spite of the above mentioned facts, we
think that the comparison of Hp-concanavalin A with
Hp-Hb estimations (i. e. calculation of the ratio) could
give valuable information on the degree of glycosylation
of Hp present in the blood of patients. During ovarian
disorders, haptoglobin, an acute phase protein, is
increased 2—5-fold, as measured by its reaction with
haemoglobin. The results of Hp-concanavalin A and Hp-
Hb measurements in all the patients with ovarian tu-
mours fall into three subgroups.
First subgroup: no differences in Hp-concanavalin A and
Hp-Hb measurements were found (ratio 0.97 ± 0.52),
possibly signifying that no differences in the degree of
branching of haptoglobin glycans were detected and that
the antennary structure of haptoglobin glycans in these
patients was similar to that present in healthy women.
Sixty percent of the ratio in non-malignant group and
30% in ovarian cancer were "normal".
Second subgroup: the Hp-concanavalin A level was sig-
nificantly higher than the Hp-Hb level (ratio higher than
1.5); this was observed in 10 and 30% of analysed sam-
ples in non-malignant and cancer disease, respectively.
These samples probably contained increased amount of
haptoglobin glycoforms with biantennary glycans.
Third subgroup: the Hp-concanavalin A level was lower
than the Hp-Hb (ratio lower than 0.45). This kind of
pattern was noticed in 30% and 40% of data in non-
malignant and cancer disease, respectively. It is pre-
dicted that these samples are rich in tri- or higher anten-
nary haptoglobin glycans, or biantennary glycans con-
taining an additional bisecting N-acetylglucosamine.
Mackiewicz & Kushner (15) have postulated that
changes in the glycosylation patterns of acute phase pro-
teins in patient sera during acute inflammation differ
from those seen in chronic inflammation. During acute
inflammation glycoproteins are characterized by higher
amounts of biantennary glycans with increased concana-
valin A reactivity. In contrast, in chronic inflammation,
a relative increase of tetra- and/or triantennary structures
with decreased concanavalin A reactivity were found.
It appears that the haptoglobin of some patients with
ovarian tumours (second subgroup) had a higher content
of biantennary glycans, while in others (third subgroup)
there was an increase of tetra- and triantennary struc-
tures. In contrast, the high fucose content in haptoglobin
from ovarian cancer patients is known to be branching-
independent (19, 21).
The results reported here are the starting point for two
further lines of study, namely oncological-gynaecologi-
cal diagnostics and the study of the structure and ar-
rangement of carbohydrates of glycoproteins synthe-
sized in the human organism under the influence of ma-
lignancy.
Last but not least we would like to point out that estima-
tions of Hp-concanavalin A and Hp-Hb are rapidly and
easily performed and not expensive, making them suit-
able for use in routine laboratory practice.
References
1. Dobryszypka W. Haptoglobin: retrospectives and perspectives.
In: Mackiewicz A, Kushner I, Baumann H, editors. Acute
phase proteins: molecular biology, biochemistry, and clinical
applications. Boca Raton, Ann Arbor, London, Tokyo: CRC
Press, 1993:185-206.
2. Jones GE, Mould DL. Adaptation of the guaiacol (peroxidase)
test for haptoglobins to a microtitration plate system. Res Vet
Sei 1984; 37:87-92.
3. Katnik I, Dobryszycka W. Development of concanavalin A-
enzyme immunosorbent assay for glycated haptoglobin using
polyclonal and monoclonal antibodies. J Immunoassay 1992;
13:145-62.
4. Van Dijk W, TXirner GA, Mackiewicz A. Changes in glycosyla-
tion of acute-phase proteins in health and disease: occurence,
regulation and function. Glycosylation and Disease 1994;
1:15-9.
Eur J Clin Chem Clki Biochem 1995; 33 (No 10)
732 K^tnik et al.: Haptoglobin in sera of patients with ovarian tumours
5. Turner GA. N-glycosylation of serum proteins in disease and
its investigation using lectins. Clin Chim Acta 1992;
208:149-71.
6. Dobryszycka W, Gerber J, Zuwala-JagieUo J, Ujec M. Acute
phase reactants and circulating immune complexes in patients
with ovarian carcinoma. Arch Immunol Ther Exp 1991;
39:41-50.
7. Katnik I, Dobryszycka W. Enzyme immunoassay to measure
low levels of haptoglobin in biological fluids. J Immunoassay
1990; 11:503-17.
8. Kottmeier HL. Report presented by the Cancer Committee to
the General Assembly of FIGO 1971; 9:178-9.
9. Hempling RE. Tumor markers in epithelial ovarian cancer.
Clinical applications. Obstet Gynecol Clinics North America
1994; 21:41-61.
10. Iwanari O, Miyako J, Date Y, Nakayama S, Kijima S, Moriy-
ama M, et al. Differential diagnosis of ovarian cancer, benign
ovarian tumor and endometriosis by a combination assay of
serum sialyl SSEA-1 antigen and CA 125 levels. Gynecol Ob-
stet Invest 1990; 29:71-4.
11. Bates SE. Clinical applications of serum tumor markers. Am
Intern Med 1991; 115: 623-38.
12. Einhorn N, Knapp RC, Bast RC, Zurawski VR. CA 125 assay
used in conjunction with CA 15-3 and TAG-72 assays for
discrimination between malignant and non-malignant diseases
of the ovary. Acta Oncologica 1989; 28:655-7.
13. Warwas M, Gerber J, Pietkiewicz A. Haptoglobin and protein-
ase inhibitors in the blood serum of women with inflammatory,
benign and neoplastic lesions of the ovary. Neoplasma 1981;
33:79-84.
14. Kushner I, Mackiewicz A. The acute phase response: an over-
view. In: Mackiewicz A, Kushner I, Baumann H, editors. Acute
phase proteins molecular biology, biochemistry, and clinical
applications. Boca Raton, Ann Arbor, London, Tokyo: CRC
Press, 1993: 3-19.
15. Taketa K, Hirai H. Lectin affinity electrophoresis of a-fetopro-
tein in cancer diagnosis. Electrophoresis 1989; 10:562-7.
16. Katnik I. Studies on haptoglobin binding to concanavalin A.
Biochim Biophys Acta 1984; 790:8-14.
17. Katnik I, Gerber J, Dobryszycka W. Affinoimmunoeleetro^
phoresis of haptoglobin with Wheat Germ Agglutinin. Diag-
nostic significance in ovarian carcinoma. Arch Immunol Ther
Exp 1987; 35:547-52. ' *
18. Katnik I, Jadach J, Krotkiewski H, Gerber J. Investigating the
glycosylation of normal and ovarian cancer haptoglobins using
digoxigenin-labelled iectins. Glycosylation and Disease 1994;
1:97-104.
19. Thompson S, Dargan E, Turner G A. Increased fucosylation
and other carbohydrate changes in haptoglobin in ovarian can-
cer. Cancer Lett 1992; 66:43-8.
20. Thompson S, Turner GA. Elevated levels of abnormally-fuco-
sylated haptoglobins in cancer sera. Br J Cancer 1987;
56:605-10.
21. Dargan E, Thompson S, Cantwell J, Wilson RG, Turner GA.
Changes in the fiicose content of haptoglobin in breast and
ovarian cancer: association with disease progression. Glycosy-
lation and Disease 1994; 1:37-43.
22. Thompson S, Cantwell BMJ, Matta KL, Turner GA. Parallel
changes in the blood levels of äbnormally-fucosylated hapto-
globin and alpha 1,3 fucosyltransferase in relationship to tu-
mour burden: more evidence for a disturbance of fucose me-
tabolism in cancer. Cancer Lett 1992; 65:115-21.
Dr Iwona Katnik
Department of Chemistry
Wroclaw University of Medicine
Bujwida 44a
PL-50-345 Wroclaw
Poland
Eur J Clin Chem Clin Biochem 1995; 33 (No 10)
